Multiparametric Markers in the Monitoring of Cancer

  • E. H. Cooper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 67)

Abstract

At the present stage of knowledge about the biochemical markers in common forms of cancer, the prospects of finding specific sensitive tumour markers look bleak. Whilst the search continues, others are turning their attention to how the markers that are presently available can be used optimally [4, 8, 10].

Keywords

Europe Lymphoma Creatinine Myeloma Ferritin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baliga, B. S., Borek, S.: Metabolism of thymine in tumour tissue: The origins of beta-aminoisobutyric acid. Adv. Enzyme Regul. 13, 27–36 (1975)PubMedCrossRefGoogle Scholar
  2. 2.
    Bastable, J. R. G., Richards, B., Haworth, S., Cooper, E. H.: Acute phase reactant proteins in the clinical management of carcinoma of the bladder, (in preparation) (1978)Google Scholar
  3. 3.
    Cooper, E. H., Bunning, R., Illingworth, S., Späti, B.: Serial measurement of β2 microglobulin, acute phase reactant proteins and ESR in non-Hodgkin’s lymphomas and chronic lymphocytic leukaemia. Biomedicine (in press) (1978)Google Scholar
  4. 4.
    Cooper, E. H., Kenny, T. E.: Biochemical profiles in tumour monitoring and their analysis. Proc. R. Soc. Med. 27, 840–843 (1977)Google Scholar
  5. 5.
    Coombes, R. C., Powles, T. J., Neville, A. M.: Evaluation of biochemical markers in breast cancer. Proc. R. Soc. Med. 70, 843–845 (1977)PubMedGoogle Scholar
  6. 6.
    Cowen, D. M., Searle, F., Milford Ward, A., Benson, E. A., Smiddy, F. G., Eaves, G., Cooper, E. H.: Multivariate biochemical indicators of breast cancer: an evaluation of the potential in routine practice. Eur. J. Cancer (in press) (1978)Google Scholar
  7. 7.
    Franchimont, P., Zangerle, P. F., Reuter, A., Hendrick, J. C., Molter, F.: Interest in simultaneous assays of several cancer associated antigens in various neoplastic disorders. In: Cancer related antigens. Franchimont, P. (ed.), p. 203. Amsterdam: North Holland 1976Google Scholar
  8. 8.
    Mach, J. P., Fritsche, R., Phan, M., Ozzello, L., Stjernswärd, J.: Search for biological markers in breast cancer. Prog. Clin. Biol. Res. 12, 91–108 (1977)PubMedGoogle Scholar
  9. 9.
    Milford Ward, A., Houghton, A. L., Cooper, E. H.: Acute phase reactant proteins in prostate cancer. Br. J. Urol.49, 411–418 (1977)CrossRefGoogle Scholar
  10. 10.
    Munro Neville, A., Cooper, E. H.: Biochemical monitoring of cancer. Ann. Clin. Biochem. 13, 283–305 (1976)PubMedGoogle Scholar
  11. 11.
    Nery, P., Munro Neville, A.: Cancer indicating substances in the urine. In: Scientific foundations of urology. Williams, D. I., Chisholm, G. D. (eds.), p. 215. London: Heinemann 1976Google Scholar
  12. 12.
    Nyholm, K. K., Sjolin, K. E., Hammer, M., Knudsen, J., Stahl, D., Nielsen, H. R.: A study of the clinical significance of urinary beta-aminoisobutyric acid in patients with urothelial tumours. Biomedicine 22, 509–516 (1975)PubMedGoogle Scholar
  13. 13.
    Wibell, L., Evrin, P. E., Berggard, I.: Serum β2 microglobulin in renal disease. Nephron 10, 320–331 (1973)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • E. H. Cooper

There are no affiliations available

Personalised recommendations